Uzé Gilles, Monneron Danièle
CNRS UMR 5124, University Montpellier II, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France.
Biochimie. 2007 Jun-Jul;89(6-7):729-34. doi: 10.1016/j.biochi.2007.01.008. Epub 2007 Jan 27.
IL-28 and IL-29 were recently described as members of a new cytokine family that shares with type I interferon (IFN) the same Jak/Stat signalling pathway driving expression of a common set of genes. Accordingly, they have been named IFN lambda. IFNs lambda exhibit several common features with type I IFNs: antiviral activity, antiproliferative activity and in vivo antitumour activity. Importantly, however, IFNs lambda bind to a distinct membrane receptor, composed of IFNLR1 and IL10R2. This specific receptor usage suggests that this cytokine family does not merely replicate the type I IFN system and justifies its designation as type III IFN by the nomenclature committee of the International Society of Interferon and Cytokine Research.
IL-28和IL-29最近被描述为一个新的细胞因子家族的成员,该家族与I型干扰素(IFN)共享相同的Jak/Stat信号通路,驱动一组共同基因的表达。因此,它们被命名为IFNλ。IFNλ与I型IFN具有几个共同特征:抗病毒活性、抗增殖活性和体内抗肿瘤活性。然而,重要的是,IFNλ与由IFNLR1和IL10R2组成的独特膜受体结合。这种特定的受体使用表明,该细胞因子家族不仅仅是复制I型IFN系统,这也证明了国际干扰素和细胞因子研究协会命名委员会将其指定为III型IFN的合理性。